Evidence map›Paper›PMID 40051286›Full record

Trial reportJournal of gynecologic oncology2025

Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.

Yidong Zhou, Fei Tong, Bowen Jin, Junjie Pan, Ning Ren, Lanqi Ren, Qiaoping Xu

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03776812 (A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03776812 phase2completednot on this map

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TypeinterventionalSponsorCorcept TherapeuticsRan2019 to 2023Enrolled178ConditionsRecurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal CarcinomaArmsRelacorilant, Nab-paclitaxel
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Request for retraction: Zhou et al.Journal of gynecologic oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yidong Zhou *Fourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou, China.ORCID 0009-0000-1234-5864
Fei Tong *Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, China.ORCID 0009-0005-5387-3141
Bowen JinFourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou, China.ORCID 0009-0006-4643-5247
Junjie PanFourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou, China.ORCID 0009-0008-7045-9454
Ning RenFourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou, China.ORCID 0009-0001-5240-1899
Lanqi RenFourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou, China.ORCID 0009-0001-9245-1321
Qiaoping XuDepartment of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Cancer Center, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China. xqp1984@126.com.ORCID 0000-0002-8327-735X

Funding

Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province 2020E10021Key Medical Discipline of Hangzhou City 2021-21Key Medical Discipline of Zhejiang Province 2018-2-3Zhejiang Province Medical and Health Science and Technology Program 2023KY933Zhejiang Traditional Chinese Medicine Science and Technology Project 2022ZA139Zhejiang Traditional Chinese Medicine Science and Technology Project 2023ZL565
6 · The paper itself

Abstract

objectiveThe phase 2, open-label, randomized, 3-arm study (NCT03776812) found that intermittently dosed relacorilant + nab-paclitaxel improved progression-free survival, duration of response, and overall survival compared with nab-paclitaxel monotherapy with minimal additional toxicity. This study analyzed the cost-effectiveness of intermittent relacorilant + nab-paclitaxel (IN), continuous relacorilant + nab-paclitaxel (CN) and nab-paclitaxel monotherapy (N) from the payer's perspective over a 5-year time horizon.

methodsThe health outcome is expressed in quality-adjusted life years (QALYs). IN, CN and N were evaluated using QALYs and incremental cost-effectiveness ratio (ICER). The data for this model come from the NCT03776812 trial and other published literature. The impact of the variables is studied using a one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis based on a second-order Monte Carlo simulation.

resultsN was the least costly strategy, at $ 4606.05, followed by IN ($22,597.75) and CN ($44,276.86). Based on a willingness-to-pay threshold of $100,000/QALY, IN was cost-effective compared with N, with an ICER of $21,418.69 per QALY gained for N, whereas CN was ruled out by extended dominance (less effective, more costly), compared with N. The incremental benefits of IN compared to CN and N were 0.72 QALYs and 0.84 QALYs.

conclusionFrom a US health care system perspective, IN may be cost-effective compared to CN for patients with recurrent platinum-resistant ovarian cancer, and IN is also better than CN and N in terms of efficacy. Therefore, IN is a high-quality regimen for clinicians to treat patients with recurrent platinum-resistant ovarian cancer.

trial registrationClinicalTrials.gov Identifier: NCT03776812.

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalOvarian NeoplasmsPaclitaxelCost-Benefit AnalysisDrug Resistance, NeoplasmFemaleHumansMiddle AgedProgression-Free SurvivalQuality-Adjusted Life Years130-nm albumin-bound paclitaxelAlbuminsPaclitaxelCost-Effectiveness AnalysisEconomic ModelOvarian NeoplasmsPaclitaxelPharmacoeconomics

Identifiers

PMID40051286
PMCPMC12226313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.